CRSP241220P30000
- 0.00
- 0.000.00%
CRISPR Therapeutics Newsroom
JMP Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $86
CRISPR Therapeutics: Promising Developments and Positive Outlook Amid Advancements in Gene-Editing
1 Big New Green Flag for CRISPR Therapeutics' Stock
Clear Street Initiates CRISPR Therapeutics(CRSP.US) With Hold Rating, Announces Target Price $45
Piper Sandler Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $105
3 Things You Need to Know If You Buy CRISPR Therapeutics Today
Is CRISPR Therapeutics AG (CRSP) the Worst ARK Stock to Buy According to Short Sellers?
Chardan Capital Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $94
Evercore Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $60
Crispr Therapeutics AG (CRSP) Gets a Hold From Evercore ISI
Analysts Are Bullish on Top Healthcare Stocks: Crispr Therapeutics AG (CRSP), Silence Therapeutics (SLN)
Chardan Capital Maintains Buy on CRISPR Therapeutics, Maintains $94 Price Target
CRISPR Therapeutics Analyst Ratings
William Blair Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
Vertex Reports Positive Long-term Data for Casgevy
CRISPR Therapeutics Highlights CTX112 Data At ASH 2024, Showcasing Potential Clinical Benefits In R/R CD19-Positive B-Cell Malignancies; Receives FDA RMAT Designation For Follicular And Marginal Zone Lymphomas, With Phase 1 Trial Expanding Into...
CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting
CRISPR Therapeutics (CRSP) Upgraded to Buy: What Does It Mean for the Stock?
CMS Rolls Out New Payment Model for Vertex, Bluebird Gene Therapies
What CRISPR Therapeutics AG's (NASDAQ:CRSP) P/S Is Not Telling You